X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (1537) 1537
Publication (168) 168
Newsletter (21) 21
Book Review (16) 16
Book Chapter (2) 2
Magazine Article (2) 2
Conference Proceeding (1) 1
Dissertation (1) 1
Newspaper Article (1) 1
Paper (1) 1
Web Resource (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (932) 932
hydroxyurea - pharmacology (694) 694
hydroxyurea (577) 577
animals (545) 545
hydroxyurea - analogs & derivatives (482) 482
index medicus (396) 396
male (370) 370
hydroxyurea - therapeutic use (326) 326
female (320) 320
mice (218) 218
pharmacology & pharmacy (215) 215
adult (212) 212
oncology (181) 181
lipoxygenase inhibitors - pharmacology (161) 161
middle aged (154) 154
biochemistry & molecular biology (152) 152
hematology (145) 145
hydroxyurea - administration & dosage (144) 144
rats (139) 139
cell line (127) 127
dose-response relationship, drug (127) 127
cancer (119) 119
cell biology (109) 109
cells, cultured (103) 103
aged (99) 99
research (93) 93
kinetics (92) 92
zileuton (90) 90
ribonucleotide reductase (88) 88
treatment outcome (86) 86
antineoplastic agents - pharmacology (85) 85
hydroxyurea - adverse effects (85) 85
therapy (84) 84
asthma - drug therapy (81) 81
dna replication - drug effects (81) 81
enzyme inhibitors - pharmacology (81) 81
mutation (80) 80
time factors (80) 80
analysis (79) 79
dna (79) 79
immunology (78) 78
leukotrienes (78) 78
expression (77) 77
anemia (76) 76
lipoxygenase inhibitors - therapeutic use (76) 76
dna - biosynthesis (74) 74
ribonucleotide reductases - antagonists & inhibitors (74) 74
sickle cell anemia (73) 73
cell cycle (72) 72
article (70) 70
asthma (70) 70
drug therapy, combination (70) 70
5-lipoxygenase (69) 69
anemia, sickle cell - drug therapy (69) 69
replication (69) 69
drug synergism (64) 64
sickle cell disease (64) 64
cells (63) 63
dna damage (62) 62
hydroxyurea - chemistry (62) 62
dna replication (61) 61
inflammation (61) 61
research article (61) 61
administration, oral (60) 60
arachidonate 5-lipoxygenase - metabolism (60) 60
chemotherapy (60) 60
double-blind method (60) 60
care and treatment (59) 59
health aspects (59) 59
in vitro techniques (59) 59
structure-activity relationship (59) 59
adolescent (58) 58
cell division - drug effects (57) 57
cell line, tumor (57) 57
cell survival - drug effects (57) 57
cytarabine - pharmacology (57) 57
physiological aspects (57) 57
lipoxygenase inhibitors (56) 56
drug resistance (55) 55
phosphorylation (55) 55
proteins (55) 55
apoptosis (54) 54
child (54) 54
disease (54) 54
antineoplastic combined chemotherapy protocols - therapeutic use (53) 53
medicine & public health (53) 53
tumor cells, cultured (53) 53
disease models, animal (52) 52
hiv infections - drug therapy (52) 52
inhibition (52) 52
drug therapy (51) 51
chemistry, medicinal (49) 49
genetics & heredity (49) 49
cell cycle - drug effects (48) 48
dna repair (48) 48
activation (47) 47
enzymes (47) 47
hydroxyurea - pharmacokinetics (47) 47
leukotriene antagonists - therapeutic use (47) 47
lipoxygenase inhibitors - administration & dosage (47) 47
more...
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (1528) 1528
Russian (7) 7
German (6) 6
Japanese (6) 6
French (5) 5
Chinese (4) 4
Polish (3) 3
Spanish (2) 2
Bulgarian (1) 1
Swedish (1) 1
Ukrainian (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Leukemia Research, ISSN 0145-2126, 2007, Volume 32, Issue 1, pp. 71 - 77
Abstract Triapine® is a potent ribonucleotide reductase (RR) inhibitor that depletes intracellular deoxyribonculeotide pools, especially dATP. We designed a... 
Hematology, Oncology and Palliative Medicine | Rbonucleotide reductase | Fludarabine | Myeloproliferative disorders | Triapine | Refractory acute leukemia | CHRONIC MYELOGENOUS LEUKEMIA | CELLS | RESPONSE CRITERIA | NERVOUS-SYSTEM TOXICITY | HYDROXYUREA | myeloproliferative disorders | rbonucleotide reductase | INTERNATIONAL WORKING GROUP | INDUCTION THERAPY | METABOLISM | ONCOLOGY | refractory acute leukemia | fludarabine | ARA-C | HEMATOLOGY | MYELODYSPLASTIC SYNDROMES | Recurrence | Pyridines - administration & dosage | Humans | Middle Aged | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Male | Treatment Outcome | Myeloproliferative Disorders - drug therapy | Vidarabine - analogs & derivatives | Thiosemicarbazones - administration & dosage | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Precursor Cell Lymphoblastic Leukemia-Lymphoma - diet therapy | Leukemia, Myeloid, Acute - drug therapy | Adult | Female | Aged | Vidarabine - administration & dosage | Myelodysplastic Syndromes - drug therapy | Antimitotic agents | Care and treatment | Oncology, Experimental | Bone marrow | Nucleosides | Clinical trials | Transplantation | Research | Antineoplastic agents | Cancer | Adenosine | nucleoside analogs | Ribonucleoside-triphosphate reductase | Toxicity | Leukemia | Malignancy | Fever | Metabolic acidosis | Myeloproliferative diseases | triapine | ribonucleotide reductase
Journal Article
Journal Article
Organic and Biomolecular Chemistry, ISSN 1477-0520, 02/2012, Volume 10, Issue 6, pp. 1196 - 1206
Journal Article
Expert Opinion on Investigational Drugs, ISSN 1354-3784, 04/2012, Volume 21, Issue 4, pp. 403 - 408
Journal Article
ChemMedChem, ISSN 1860-7179, 09/2010, Volume 5, Issue 9, pp. 1444 - 1449
Multitarget drugs: The title compounds represent the first class of dual‐action drugs with 5‐LO inhibition and NO‐dependent activities. They block leukotriene... 
zileuton | nitric oxide donors | drug design | inflammation | 5‐LO inhibitors | Nitric oxide donors | Drug design | Inflammation | 5-LO inhibitors | Zileuton | CHEMISTRY, MEDICINAL | ACID | MOIETIES | DISEASES | PATHWAY | 5-LIPOXYGENASE INHIBITORS | NITRIC-OXIDE | PHARMACOLOGY & PHARMACY | CYSTEINYL-LEUKOTRIENES
Journal Article
Zeitschrift für Naturforschung B, ISSN 0932-0776, 01/2003, Volume 58, Issue 1, pp. 106 - 110
Benzyloxyureas (4) have been prepared by reactions of diethyl 3-benzyloxyamino-propyl-phosphonate (3) with isocyanates, potassium cyanate or... 
Malaria tropica | Fosmidomycin | Hydroxyurea Analogues | PHOSPHONIC ACID | fosmidomycin | hydroxyurea analogues | CHEMISTRY, ORGANIC | malaria tropica | INHIBITORS | CHEMISTRY, INORGANIC & NUCLEAR
Journal Article
Journal Article
Molecular Cancer Therapeutics, ISSN 1535-7163, 02/2012, Volume 11, Issue 2, pp. 427 - 438
Journal Article
Journal of Clinical Oncology, ISSN 0732-183X, 05/2017, Volume 35, Issue 14, pp. 1591 - 1597
Journal Article